Schroder Investment Management Group Decreases Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)

Schroder Investment Management Group lowered its stake in Cytokinetics, Incorporated (NASDAQ:CYTK) by 97.4% during the 4th quarter, HoldingsChannel reports. The firm owned 149,433 shares of the biopharmaceutical company’s stock after selling 5,536,292 shares during the period. Schroder Investment Management Group’s holdings in Cytokinetics were worth $7,046,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Jones Financial Companies Lllp boosted its stake in shares of Cytokinetics by 189.8% in the 4th quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 374 shares during the last quarter. Retirement Systems of Alabama lifted its holdings in Cytokinetics by 0.4% in the fourth quarter. Retirement Systems of Alabama now owns 143,495 shares of the biopharmaceutical company’s stock valued at $6,750,000 after acquiring an additional 565 shares during the period. Arizona State Retirement System lifted its holdings in Cytokinetics by 1.9% in the fourth quarter. Arizona State Retirement System now owns 32,366 shares of the biopharmaceutical company’s stock valued at $1,522,000 after acquiring an additional 600 shares during the period. Inspire Investing LLC boosted its position in Cytokinetics by 7.8% in the fourth quarter. Inspire Investing LLC now owns 8,504 shares of the biopharmaceutical company’s stock worth $400,000 after purchasing an additional 616 shares during the last quarter. Finally, Centricity Wealth Management LLC bought a new stake in shares of Cytokinetics during the 4th quarter valued at about $29,000.

Insider Buying and Selling

In other news, EVP Andrew Callos sold 3,341 shares of the business’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $43.27, for a total value of $144,565.07. Following the sale, the executive vice president now directly owns 64,434 shares in the company, valued at $2,788,059.18. The trade was a 4.93 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Robert I. Blum sold 16,970 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $43.44, for a total transaction of $737,176.80. Following the completion of the transaction, the chief executive officer now directly owns 364,181 shares of the company’s stock, valued at approximately $15,820,022.64. The trade was a 4.45 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 59,284 shares of company stock worth $2,578,268. Insiders own 3.40% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on CYTK shares. Citigroup began coverage on shares of Cytokinetics in a report on Friday, February 7th. They issued a “buy” rating and a $86.00 price objective on the stock. Needham & Company LLC reissued a “buy” rating and set a $72.00 price objective on shares of Cytokinetics in a research report on Thursday, February 6th. Stifel Nicolaus began coverage on Cytokinetics in a report on Wednesday, January 22nd. They issued a “buy” rating and a $80.00 target price on the stock. Evercore ISI upgraded Cytokinetics to a “strong-buy” rating in a research report on Friday, February 7th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $78.00 price objective on shares of Cytokinetics in a research report on Friday, February 7th. Two analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $82.00.

Cytokinetics Stock Down 7.8 %

CYTK opened at $37.36 on Friday. The company has a market capitalization of $4.42 billion, a PE ratio of -6.94 and a beta of 0.94. The firm has a 50-day simple moving average of $44.93 and a two-hundred day simple moving average of $49.03. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 5.93. Cytokinetics, Incorporated has a 52 week low of $36.89 and a 52 week high of $75.71.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, beating the consensus estimate of ($1.29) by $0.03. The firm had revenue of $16.93 million for the quarter, compared to analysts’ expectations of $14.26 million. Analysts forecast that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.